Welcome to our searchable resource and literature collection on safer supply and related topics.
Found a broken link? Links do move around, so if you find one here that's broken, please let us know through the Contact form.
This systematic review aims to assess the efficacy of pharmacotherapy for methamphetamine withdrawal, the first comprehensive meta-analysis since 2008.
The study aims to provide insight into the lives of parents to adult children with drug addiction.
Following hospitalization with an injecting-related infection, use of opioid agonist treatment (OAT; methadone or buprenorphine) may be associated with reduced risk of death or rehospitalization wi
It is unclear how patients experience and adjust to losing the possibility of achieving an opioid effect.
Different combinations of substance use and mental health problems require different treatment approaches.
We used cross-national data to examine associations of diverse traumatic events (TEs) with SUD onset, and variation in associations over time.
The current study expands on and integrates previous theoretical models concerning the pathways that link child maltreatment to substance use disorder.
We utilized a newly developed, statewide database to describe epidemiologic characteristics and healthcare utilization among patients with (DU-IE) and without (non-DU-IE) drug use-associated infect
At the onset of the COVID-19 pandemic, federal agencies acted quickly to remove a legal barrier, effectively allowing people with opioid used disorder (OUD) to initiate buprenorphine treatment via
Although several studies have found a high incidence of coexisting mental health problems among adolescents with substance use problems, follow-up studies addressing how these conditions change ove
Barriers are prevalent in less populated areas where treatment options are limited.
This study examined the perspective of 163 American Indian and Alaska Native people (AIAN) in California to assess culturally based or traditional healing treatment modalities to treat opioid/subst
In March 2020, the Substance Abuse and Mental Health Services Administration (SAMHSA) issued guidance allowing for the expansion of take-home methadone doses.
To limit COVID-19 spread and to avoid disruptions in access to medications for opioid use disorder (MOUD), including buprenorphine and methadone, US federal and state agencies granted unprecedented
Some Rights Reserved National Safer Supply Community of Practice
